BACKGROUND: Hospital readmissions among patients with diabetes are substantial and costly. Although prior studies have shown that receipt of outpatient quality of care significantly reduces the risk of hospitalization among patients with diabetes, little is known about its impact on hospital readmission. The objective of this study is to assess the impact of outpatient quality of care on 30-day readmission among patients with diabetes. METHODS: We used deidentified administrative claims data from the IMS LifeLink and included commercially insured diabetes patients ≥ 19 years old discharged from hospitals in the United States in 2009 and 2010 (n = 30,139). The outcome was readmission within 2-30 days of discharge. The main independent variables were receipt of outpatient quality-of-care measures (i.e., two hemoglobin A1c tests, low-density lipoprotein (LDL) test, 90-day supply of statin, and 90-day supply of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers). Multivariate logistic regression was used to examine the impact of outpatient quality of care on hospital readmission while controlling for demographics, clinical characteristics, health care utilization, and insurance type in the year prior to admission. RESULTS: Overall 30-day readmission rates among patients with diabetes were 18.9%. Patients who received at least one LDL test [odds ratio (OR) = 0.918, 95% confidence interval (CI; 0.852 0.989), p < .025] and ≥90-day supply of statins (OR = 0.91, 95% CI [0.85 0.97], p < .01) were less likely to be readmitted to the hospital. CONCLUSIONS: Receipt of LDL testing and adherence to statin medications were effective in decreasing the likelihood of 30-day hospital readmission and may be considered as elements of a quality focused incentive-based health care delivery package for diabetes patients.
BACKGROUND: Hospital readmissions among patients with diabetes are substantial and costly. Although prior studies have shown that receipt of outpatient quality of care significantly reduces the risk of hospitalization among patients with diabetes, little is known about its impact on hospital readmission. The objective of this study is to assess the impact of outpatient quality of care on 30-day readmission among patients with diabetes. METHODS: We used deidentified administrative claims data from the IMS LifeLink and included commercially insured diabetespatients ≥ 19 years old discharged from hospitals in the United States in 2009 and 2010 (n = 30,139). The outcome was readmission within 2-30 days of discharge. The main independent variables were receipt of outpatient quality-of-care measures (i.e., two hemoglobin A1c tests, low-density lipoprotein (LDL) test, 90-day supply of statin, and 90-day supply of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers). Multivariate logistic regression was used to examine the impact of outpatient quality of care on hospital readmission while controlling for demographics, clinical characteristics, health care utilization, and insurance type in the year prior to admission. RESULTS: Overall 30-day readmission rates among patients with diabetes were 18.9%. Patients who received at least one LDL test [odds ratio (OR) = 0.918, 95% confidence interval (CI; 0.852 0.989), p < .025] and ≥90-day supply of statins (OR = 0.91, 95% CI [0.85 0.97], p < .01) were less likely to be readmitted to the hospital. CONCLUSIONS: Receipt of LDL testing and adherence to statin medications were effective in decreasing the likelihood of 30-day hospital readmission and may be considered as elements of a quality focused incentive-based health care delivery package for diabetespatients.
Authors: B M Psaty; N L Smith; D S Siscovick; T D Koepsell; N S Weiss; S R Heckbert; R N Lemaitre; E H Wagner; C D Furberg Journal: JAMA Date: 1997-03-05 Impact factor: 56.272
Authors: Judy Ying Chen; Ning Kang; Deborah Taira Juarez; Krista A Hodges; Richard S Chung; Antonio P Legorreta Journal: J Healthc Qual Date: 2010 Jan-Feb Impact factor: 1.095
Authors: Tomas Berl; Lawrence G Hunsicker; Julia B Lewis; Marc A Pfeffer; Jerome G Porush; Jean-Lucien Rouleau; Paul L Drury; Enric Esmatjes; Donald Hricik; Chirag R Parikh; Itamar Raz; Philippe Vanhille; Thomas B Wiegmann; Bernard M Wolfe; Francesco Locatelli; Samuel Z Goldhaber; Edmund J Lewis Journal: Ann Intern Med Date: 2003-04-01 Impact factor: 25.391
Authors: E Z Oddone; M Weinberger; M Horner; C Mengel; F Goldstein; P Ginier; D Smith; J Huey; N J Farber; D A Asch; L Loo; E Mack; A G Hurder; W Henderson; J R Feussner Journal: J Gen Intern Med Date: 1996-10 Impact factor: 5.128
Authors: John J V McMurray; Jan Ostergren; Karl Swedberg; Christopher B Granger; Peter Held; Eric L Michelson; Bertil Olofsson; Salim Yusuf; Marc A Pfeffer Journal: Lancet Date: 2003-09-06 Impact factor: 79.321
Authors: Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Salim Yusuf; Stuart Pocock Journal: Lancet Date: 2003-09-06 Impact factor: 79.321
Authors: Daniel J Rubin; Elizabeth A Handorf; Sherita Hill Golden; Deborah B Nelson; Marie E McDonnell; Huaqing Zhao Journal: Endocr Pract Date: 2016-10 Impact factor: 3.443
Authors: Elias K Spanakis; Guillermo E Umpierrez; Tariq Siddiqui; Min Zhan; Soren Snitker; Jeffrey C Fink; John D Sorkin Journal: J Clin Endocrinol Metab Date: 2019-09-01 Impact factor: 5.958
Authors: Naomi Launders; Kate Dotsikas; Louise Marston; Gabriele Price; David P J Osborn; Joseph F Hayes Journal: PLoS One Date: 2022-08-18 Impact factor: 3.752
Authors: Claudia Fischer; Hester F Lingsma; Perla J Marang-van de Mheen; Dionne S Kringos; Niek S Klazinga; Ewout W Steyerberg Journal: PLoS One Date: 2014-11-07 Impact factor: 3.240
Authors: Elias K Spanakis; Lakshmi G Singh; Tariq Siddiqui; John D Sorkin; George Notas; Michelle F Magee; Jeffrey C Fink; Min Zhan; Guillermo E Umpierrez Journal: BMJ Open Diabetes Res Care Date: 2020-05